NICE rare-disease modifier consultation is reshaping HTA for ultra-rare therapies

Reading the signal

NICE introduced a severity modifier and a rare-disease threshold into its technology appraisal framework as part of the 2022 methods review. The framework allows higher cost-per-QALY thresholds for severe conditions and for very rare conditions, with explicit criteria for each.

The current consultation reopens both. The consultation document and the responses submitted to date make several axes visible:

• Whether the rare-disease threshold should be defined by population size (the current 1-in-50,000 threshold), by disease severity, or by both
• Whether the highly specialised technologies (HST) route, with its higher cost-per-QALY threshold, should remain a separate route or be integrated into the standard technology appraisal route with the rare-disease modifier
• Whether the severity modifier should be applied additively or multiplicatively against the rare-disease modifier when both apply

The submitted responses are diverging. Sponsors and patient groups generally argue for retention or expansion of the rare-disease threshold; some payer-side responses argue for tightening or removal. The clinician responses are split across both positions.

Commercial implications

For sponsors of orphan and ultra-orphan assets in development:

1. Submission timing relative to the consultation outcome is now a commercial variable. Programs targeting NICE submission in 2027 onward need to plan for either the current framework or a substantially revised one, and that uncertainty is itself a commercial planning problem.
2. The HST route question is high-stakes. If HST is integrated into standard TA, the cost-per-QALY headroom available to ultra-rare therapies could compress materially. If it is retained, the route stays distinctive.
3. Population-size definition versus severity definition is the most decisive technical detail. A severity-only threshold removes the protection that the population-size threshold provides for ultra-rare therapies that may not meet the severity criteria typically used in onco-haem and end-of-life conditions.

What we are watching

• The consultation closure date and the NICE board response timing
• The submitted consultation responses as they become public, and any visible signal on which direction the framework is moving
• Adjacent HTA bodies (SMC in Scotland, AWMSG in Wales, AOTMiT in Poland) and whether they signal a coordinated or divergent direction on the rare-disease modifier question